Pegaferon and Ribavirin for Hepatitis C

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of a locally produced 40KD pegylated interferon alpha-2a (Pegaferon) in patients with hepatitis C. 100 patients will be treated using standard guidelines for hepatitis C. Response to treatment and side effects will be recorded.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tehran University of Medical Sciences
• Collaborator: Pars No Tarkib Co
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons; Peginterferon alfa-2a; Ribavirin

Criteria

Inclusion Criteria:

• Chronic hepatitis C

• Age between 15 and 65

Exclusion Criteria:

• previous treatment for chronic hepatitis C

• co-infection with human immunodeficiency virus or hepatitis B virus

• major thalassemia or hemophilia

• active drug user

• being treated for major depression or psychosis

• decompensated cirrhosis

• serum creatinine > 1.5 mg/dL

• solid organ transplant

• untreated thyroid disease

• uncontrolled diabetes mellitus

• uncontrolled autoimmune disease

• advanced cardiac or pulmonary disease.

• planning to become pregnant in the next 1.5 years

• patients with inadequate contraception

• not consenting to the study